RE:RE:Any Idea Why?...Elliot gambled on news before the awful fall financing, and now he's done the same with the spring rally that never materialized. Withdrawing one prospectus filing is most likely only a prelude to filing another with even worse terms as Elliot has bet yet again on aducanumab news, this time in June.
Any exec with an ounce of integrity would look at this situation and either change the strategy or double down by adjusting their compensation to cover the gap.